These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24190547)

  • 1. Advances in cellular therapy: 7th international symposium on the clinical use of cellular products, March 14 and 15, 2013, Erlangen, Germany.
    Aigner M; Bruns H; Gary R; Jitschin R; Kremer A; Mougiakakos D; Völkl S; Mackensen A; Gerbitz A
    Cancer Immunol Immunother; 2014 Feb; 63(2):185-93. PubMed ID: 24190547
    [No Abstract]   [Full Text] [Related]  

  • 2. The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell Population.
    Ju X; Silveira PA; Hsu WH; Elgundi Z; Alingcastre R; Verma ND; Fromm PD; Hsu JL; Bryant C; Li Z; Kupresanin F; Lo TH; Clarke C; Lee K; McGuire H; Fazekas de St Groth B; Larsen SR; Gibson J; Bradstock KF; Clark GJ; Hart DN
    J Immunol; 2016 Dec; 197(12):4613-4625. PubMed ID: 27837105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nsp1α of Porcine Reproductive and Respiratory Syndrome Virus Strain BB0907 Impairs the Function of Monocyte-Derived Dendritic Cells via the Release of Soluble CD83.
    Chen X; Bai J; Liu X; Song Z; Zhang Q; Wang X; Jiang P
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29793955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD83 expression on dendritic cells and T cells: correlation with effective immune responses.
    Aerts-Toegaert C; Heirman C; Tuyaerts S; Corthals J; Aerts JL; Bonehill A; Thielemans K; Breckpot K
    Eur J Immunol; 2007 Mar; 37(3):686-95. PubMed ID: 17301951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease.
    Wilson J; Cullup H; Lourie R; Sheng Y; Palkova A; Radford KJ; Dickinson AM; Rice AM; Hart DN; Munster DJ
    J Exp Med; 2009 Feb; 206(2):387-98. PubMed ID: 19171763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.
    Seldon TA; Pryor R; Palkova A; Jones ML; Verma ND; Findova M; Braet K; Sheng Y; Fan Y; Zhou EY; Marks JD; Munro T; Mahler SM; Barnard RT; Fromm PD; Silveira PA; Elgundi Z; Ju X; Clark GJ; Bradstock KF; Munster DJ; Hart DN
    Leukemia; 2016 Mar; 30(3):692-700. PubMed ID: 26286117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Porcine CD83 is a glycosylated dimeric protein existing naturally in membrane-bound and soluble forms.
    Huo S; Zhang J; Wu F; Zuo Y; Cui D; Li X; Zhong Z; Zhong F
    Dev Comp Immunol; 2019 Jan; 90():60-69. PubMed ID: 30193829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane-bound and soluble porcine CD83 functions antithetically in T cell activation and dendritic cell differentiation in vitro.
    Huo S; Zhang J; Liang S; Wu F; Zuo Y; Cui D; Zhang Y; Zhong Z; Zhong F
    Dev Comp Immunol; 2019 Oct; 99():103398. PubMed ID: 31121186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CD83 in the murine immune system.
    Wolenski M; Cramer SO; Ehrlich S; Steeg C; Grossschupff G; Tenner-Racz K; Racz P; Fleischer B; von Bonin A
    Med Microbiol Immunol; 2003 Nov; 192(4):189-92. PubMed ID: 12687354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells.
    Lechmann M; Krooshoop DJ; Dudziak D; Kremmer E; Kuhnt C; Figdor CG; Schuler G; Steinkasserer A
    J Exp Med; 2001 Dec; 194(12):1813-21. PubMed ID: 11748282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD83 Antibody Inhibits Human B Cell Responses to Antigen as well as Dendritic Cell-Mediated CD4 T Cell Responses.
    Wong KY; Baron R; Seldon TA; Jones ML; Rice AM; Munster DJ
    J Immunol; 2018 May; 200(10):3383-3396. PubMed ID: 29643191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression involving soluble CD83 induces tolerogenic dendritic cells that prevent cardiac allograft rejection.
    Ge W; Arp J; Lian D; Liu W; Baroja ML; Jiang J; Ramcharran S; Eldeen FZ; Zinser E; Steinkasserer A; Chou P; Brand S; Nicolette C; Garcia B; Wang H
    Transplantation; 2010 Dec; 90(11):1145-56. PubMed ID: 20861805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations in vivo.
    Lechmann M; Shuman N; Wakeham A; Mak TW
    Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11887-92. PubMed ID: 18701714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
    Peggs KS; Mackinnon S
    Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo.
    Prazma CM; Yazawa N; Fujimoto Y; Fujimoto M; Tedder TF
    J Immunol; 2007 Oct; 179(7):4550-62. PubMed ID: 17878352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation.
    Prechtel AT; Turza NM; Theodoridis AA; Steinkasserer A
    J Immunol; 2007 May; 178(9):5454-64. PubMed ID: 17442926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD83: an update on functions and prospects of the maturation marker of dendritic cells.
    Prechtel AT; Steinkasserer A
    Arch Dermatol Res; 2007 May; 299(2):59-69. PubMed ID: 17334966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of nucleocytoplasmic trafficking of the HuR ligand APRIL and its influence on CD83 expression.
    Fries B; Heukeshoven J; Hauber I; Grüttner C; Stocking C; Kehlenbach RH; Hauber J; Chemnitz J
    J Biol Chem; 2007 Feb; 282(7):4504-4515. PubMed ID: 17178712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.
    Cieri N; Mastaglio S; Oliveira G; Casucci M; Bondanza A; Bonini C
    Immunol Rev; 2014 Jan; 257(1):165-80. PubMed ID: 24329796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.
    Klangsinsirikul P; Carter GI; Byrne JL; Hale G; Russell NH
    Blood; 2002 Apr; 99(7):2586-91. PubMed ID: 11895797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.